Stay updated on Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Sign up to get notified when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.

Latest updates to the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe clinical-trial record is now displayed, including the study design, eligibility criteria, treatment arms, outcome measures, and record dates. The study is marked completed and no longer recruiting.SummaryDifference52%

- Check19 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site as revision v3.8.0 instead of v3.7.2. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide NIH banner announces website transition updates and says NIH content may use “Super Intelligence” in place of “Artificial Intelligence.” No clinical-trial details are provided.SummaryDifference1%

- Check33 days agoChange DetectedThe footer’s displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the previous study content with an access-restricted message. The layout remains with header and footer visible, indicating the record is currently inaccessible.SummaryDifference18%

Stay in the know with updates to Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.